Home > Search Results

Results: 11

An individual patient-based meta-analysis of the effects of dronedarone in patients with atrial fibrillation

AIMS: Dronedarone is a non-iodinated benzofuran derivative with antiarrhythmic properties. In placebo-controlled atrial fibrillation (AF) trials, the drug was found to have divergent effects on endpoints such as cardiovascular death or hospitalization. The objective of this meta-analysis of all placebo-controlled studies was to provide insights on possible reasons for these divergent effects.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2014

Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation

This review compared the efficacy and safety of dronedarone versus amiodarone for the prevention of recurrent atrial fibrillation. It concluded that dronedarone was less effective than amiodarone, but had fewer adverse events. Limitations in the conduct and reporting of this review mean that the estimates on which these conclusions were based may not be reliable.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2009

Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation

The review concluded that all the included antiarrhythmic drugs were efficacious in delaying recurrence of atrial fibrillation. Amiodarone was the most effective in maintaining sinus rhythm. Sotalol and possibly amiodarone increased mortality. Dronedarone possibly decreased serious adverse events and proarrhythmia. The poor quality of many of the included trials and differences across trials limits the reliability of pooled results.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2011

Dronedarone and the incidence of stroke in patients with paroxysmal or persistent atrial fibrillation: a systematic review and meta-analysis of randomized trials

The review found evidence to indicate that dronedarone reduced the risk of stroke or transient ischaemic attack in individuals with paroxysmal or persistent atrial fibrillation, but more research was needed. These conclusions require some caution in interpretation due to lack of significant findings in the random-effects model and a lack of studies in which stroke was a prespecified outcome.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2011

Meta-analysis of cardiovascular outcomes with dronedarone in patients with atrial fibrillation or heart failure

This review concluded that, compared to controls, pooled analysis showed increased all-cause and cardiovascular mortality and increased heart failure exacerbations with dronedarone in a wide spectrum of populations; therefore, it should be used with caution especially in those with cardiovascular risk factors. As the authors conclusions depend on questionable sensitivity analyses they should be treated with some caution.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2012

Antiarrhythmics for maintaining sinus rhythm after reversing atrial fibrillation

Atrial fibrillation is a disease where the heart rhythm is irregular (this is called arrhythmia) and too fast (this is called tachycardia, from the Greek tachy meaning fast). Atrial fibrillation may produce complications, either in the heart (heart failure, syncope) or in other organs (mainly causing embolism, the formation of blood clots in the cavities of the heart that may then travel to other places, for example the brain).

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2015

Atrial Fibrillation: The Management of Atrial Fibrillation

Atrial fibrillation (AF) is a very common problem. In England alone, approximately 835,000 people have AF.321 Through its effects on rate and rhythm, it is a major cause of morbidity. Through increasing susceptibility to stroke, it is a major cause of both morbidity and mortality.

NICE Clinical Guidelines - National Clinical Guideline Centre (UK).

Version: June 2014
Show search results within this document

Catheter Ablation for Treatment of Atrial Fibrillation [Internet]

This report evaluates the current state of evidence regarding effectiveness and harms of catheter ablation for atrial fibrillation (AF) with a focus on longer-term outcomes and evidence relevant to the Medicare population.

Technology Assessment Report - Agency for Healthcare Research and Quality (US).

Version: April 20, 2015
Show search results within this document

Assessment on Implantable Defibrillators and the Evidence for Primary Prevention of Sudden Cardiac Death [Internet]

Implantable cardioverter–defibrillators (ICDs) are battery-powered implantable devices that monitor heart rhythm and deliver therapy in the form of either electric shock or antitachycardia pacing (ATP) when a life-threatening ventricular arrhythmia is detected. ICDs have been used in patients who survived sustained ventricular arrhythmias to prevent sudden cardiac death (SCD). In recent years, ICDs have also been implanted for primary prevention (prevention of SCD in a patient who has not had yet had sustained ventricular tachyarrhythmia but has risk factors for it). ICDs may also include cardiac resynchronization therapy (CRT) for additional treatment of heart failure in patients with dyssynchronous ventricles.

Technology Assessment Report - Agency for Healthcare Research and Quality (US).

Version: June 26, 2013
Show search results within this document

Interventions for the treatment of atrial fibrillation: a systematic literature review and meta-analysis

BACKGROUND: To perform a systematic review/meta-analysis evaluating the efficacy and safety of anti-arrhythmic drugs (AADs) in the treatment of atrial fibrillation (AF).

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: a meta-analysis

This meta-analysis assessed the efficacy and safety of amiodarone compared with placebo or rate-control drugs for treating persistent atrial fibrillation, in terms of mortality, rhythm control, withdrawal from treatment, and hospitalisation. The authors concluded that amiodarone was safe and effective, but some patients might be unable to tolerate it. These conclusions appear to be broadly reliable.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2009

Systematic Reviews in PubMed

See all (42)...

Systematic Review Methods in PubMed

See all (1)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...